Patient reported outcome measures (PROMs) in inflammatory bowel disease: New data

Journal of Crohn's and Colitis

Volumn 11, Issue , 2017, Pages S576-S585

  Bojic, Daniela ^a,b   Bodger, Keith ^c,d   Travis, Simon ^e  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Tillotts Pharma UK Ltd   (Switzerland)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trials; Crohn's disease; Patient reported outcome measures; Questionnaires; Ulcerative colitis

Indexed keywords

BIOASSAY; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; CROHN DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASES; PATIENT-REPORTED OUTCOME; PRACTICE GUIDELINE; PROCEDURES; QUESTIONNAIRE; STANDARDS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; ENDPOINT DETERMINATION; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT REPORTED OUTCOME MEASURES; PRACTICE GUIDELINES AS TOPIC; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85018783898     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw187     Document Type: Article

References (45)

1. Van Assche G, Dignass A, Panes J, et al.; for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
2. Dignass A, Eliakim R, Magro F, et al.; for the European Crohn's and Colitis Organisation (ECCO). The second European Consensus on the diagnosis and management of ulcerative colitis: definition and diagnosis. J Crohns Colitis 2012;6:965-90.
3. Khanna R, Jairath V, van De Casteele N, et al. Efficient early drug development for ulcerative colitis. Gastroenterology 2016;150:1056-60.
4. Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): A mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2016;1:15-24.
5. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. Ann Intern Med 2015;162:55-63.
6. Walsh AJ, Ghosh A, Brain AO, et al. Comparing disease activity indices for ulcerative colitis. J Crohns Colitis 2014; 8:318-25.
7. Peyrin Biroulet L, Sandborn WJ, Sands B, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for Treat-to-Target. Am J Gastroenterol 2015; 110:1324-38.
8. Siegel CA, Whitman CB, Spiegel BM, et al. Development of an index to define overall disease severity in IBD. Gut 2016. ePub Oct 25. pii: gutjnl-2016-312648. doi:10. 1136/gutjnl-2016-312648.
9. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
10. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-6.
11. Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148:37-51.
12. Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic measure of disease control from the patient's perspective: The IBD-Control questionnaire. Gut 2014;63:1092-1102.
13. US Food and Drug Administration Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2009.
14. Marquis P CM, Emery M. The role of health-related quality of life data in the drug approval processes in the US and Europe: A review of guidance documents and authorizations of medicinal products from 2006 to 2010. Pharm Med [serial on the Internet] 2011; 25:147-60.
15. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
16. Cheung WY, Garratt AM, Russell IT, et al. The UK IBDQ-A British version of the inflammatory bowel disease questionnaire: development and validation. J Clin Epidemiol 2000;53:297306.
17. Fitzpatrick RD, Davy C, Buxton MJ, et al. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2:3-47.
18. United States Department for Health. FDA Guidance for industry: patientreported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
19. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
20. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56.
21. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
23. Jenkinson C, Gray A, Doll H, et al. Evaluation of index and profil measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997;35:1109-118.
24. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241-7.
25. Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
26. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18[Suppl 1]:S79-S83.
27. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
28. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
29. Higgins PDR. Development of the Crohn's Disease, Patient-Reported Outcomes (CD-PRO) Questionnaire in Adults. University of Michigan at Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT 3 March 2015). http://www. great3. org/wp-content/ uploads/2015/04/Development-of-the-Crohn%E2%80%99s-Disease-Patient-Reported-Outcomes-CD-PRO-Questionnaire-in-Adults-Peter-D. R.-Higgins. pdf.
30. Atreja A, Khan S, Rogers JD, et al. Impact of the Mobile HealthPROMISE Platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of a pragmatic randomized controlled trial. JMIR Res Protoc 2015;4:e23
31. Con D, De Cruz P. Mobile phone apps for inflammatory bowel disease self-management: A systematic assessment of content and tools. JMIR Mhealth Uhealth 2016;4:e13.
32. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007;10:S125-37.
33. Patrick DL, Burke LB, Gwaltney CJ. Content validity-establishing and reporting the evidence in newly developed Patient-Reported Outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health 2011;14:967-77.
34. Dawson J, Doll H, Fitzpatrick R, et al. The routine use of patient reported outcome measures in healthcare settings. Br Med J 2010;340:c186.
35. European Medicines Agency. Reflection Paper on the Regulatory Guidance for the Use of Health Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. London: European Medicines Agency, 2005.
36. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration, February 15, 2001. Value Health 2003;6:522-31.
37. Lasch KE, Marquis P, Vigneux M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res 2010;19:1087-96.
38. Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gastroenterology 2013;145:987-95.
39. Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol 2016;13:567-79.
40. Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: The development of patient reported outcome measures for the assesment of Crohn's disease activity. Aliment Pharmacol Ther 2015;41:77-86.
41. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
42. Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987;32:64S-6S.
43. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75.
44. Jairath V, Khanna R, Zou GY, et al. Development of interim patientreported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther 2015;42:1200-10.
45. Seagrove AC, Alam MF, Alrubaiy L, et al. Randomised controlled trial. Comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: Trial design and protocol (CONSTRUCT). BMJ Open 2014;4:e005091.